Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.45 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.44 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.44 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16570272 | 0.84 | CHRNB2 (0.52) | CHEK1ALDH1A1GBA1CYP1A2 | |
| SCHEMBL1570038 | 0.83 | AR (0.44) | HTTPIK3CAPIK3CBPIK3CGPLOD2 | |
| SCHEMBL1570304 | 0.78 | RPS6KA3 (0.53) | PIK3CARPS6KA3 | |
| SCHEMBL3728634 | 0.76 | RPS6KA3 (0.46) | SMN1; SMN2ALDH1A1PLOD2PLOD3PLOD1 | |
| SCHEMBL7953768 | 0.75 | CYP2A6 (0.65) | SMN1; SMN2ALDH1A1HTTTP53DYRK1A | |
| SCHEMBL1312340 | 0.74 | PIK3CA (0.60) | SMN1; SMN2ALDH1A1HTTPIK3CAPIK3CB | |
| SCHEMBL256566 | 0.74 | CHRNB2 (0.59) | SMN1; SMN2ALDH1A1HTTPLOD2PLOD3 | |
| SCHEMBL29442130 | 0.74 | CHRNB2 (0.59) | SMN1; SMN2ALDH1A1HTTPLOD2PLOD3 | |
| SCHEMBL1570123 | 0.74 | BMPR1B (0.45) | CHEK1PIK3CALRRK2 | |
| SCHEMBL27845768 | 0.74 | AR (0.72) | CHEK1SMN1; SMN2ALDH1A1HTTPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102123991-A | 2-arylaminoquinazolines for the treatment of proliferative diseases | NOVARTIS AG | 2011-07-13 | — | — | CN | disclosed |
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| EP-2307385-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| CN-101652352-A | Quinazolines for PDK1 inhibition | NOVARTIS VACCINES & DIAGNOSTIC | 2010-02-17 | — | — | CN | disclosed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | CHEK1 163/4885SMN1; SMN2 3375/4885ALDH1A1 2630/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | CHEK1 320/4885SMN1; SMN2 2726/4885ALDH1A1 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.